AI assistant
Sending…
aTYR PHARMA INC — Director's Dealing 2020
Feb 11, 2020
34337_dirs_2020-02-11_5f5bb40f-90fa-446e-b097-6e9f92344a69.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2020-02-10
Reporting Person: SCHIMMEL PAUL (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-10 | Common Stock | P | 254000 | $4.25 | Acquired | 437590 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2890 | Direct |
| Common Stock | 63023 | Indirect |
Footnotes
F1: Represents shares purchased in an underwritten public offering at a public offering price of $4.25 per share.
F2: There shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000.
F3: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel.
More from aTYR PHARMA INC
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 11
Regulatory Filings
2026
Mar 26
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9